PCK 6.67% 2.8¢ painchek ltd

Ann: ePAT and PainChek continue to achieve commercial milestones, page-20

  1. 1,047 Posts.
    lightbulb Created with Sketch. 130
    Exactly Zmans - management don't need the big contracts to attract the big investor money, they only need to prove this model is working, Roche recently wrote a big cheque for Accuchek - so they could include it in their portfolio, that was also a Phillip Daffas ideal
    https://www.roche.com/media/store/releases/med-cor-2017-06-30.htm
    No prizes for guessing the exit strategy here
 
watchlist Created with Sketch. Add PCK (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.